PMID- 24429183
OWN - NLM
STAT- MEDLINE
DCOM- 20141028
LR  - 20220408
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 41
IP  - 3
DP  - 2014 Mar
TI  - Reliability and clinically important improvement thresholds for osteoarthritis 
      pain and function scales: a multicenter study.
PG  - 509-15
LID - 10.3899/jrheum.130609 [doi]
AB  - OBJECTIVE: To assess the reliability and clinically meaningful thresholds of 
      intermittent and constant osteoarthritis pain (ICOAP) score, the Knee injury and 
      Osteoarthritis Outcome Score Physical function Short-form (KOOS-PS), the Hip 
      disability and Osteoarthritis Outcome Score Physical function Short-form 
      (HOOS-PS), and the Quality of life subscales of HOOS/KOOS (HOOS-QOL/KOOS-QOL) in 
      patients with knee or hip arthritis. METHODS: One hundred and ninety-five 
      patients (141 knee, 54 hip) seen at 2 orthopedic outpatient clinics with a 
      diagnosis of knee or hip OA completed patient-reported questionnaires (ICOAP pain 
      scale, KOOS-PS, HOOS-PS, KOOS-QOL, HOOS-QOL) at baseline and 2-week followup. 
      Reliability was assessed using intraclass correlation coefficients (ICC). We 
      calculated minimum clinically important difference (MCID) and moderate 
      improvement in the subgroup that reported change in the status of their affected 
      joint. RESULTS: The reliability as assessed by ICC was as follows: ICOAP pain 
      scale, 0.63 (0.48, 0.74) in patients with knee arthritis, and 0.86 (0.73, 0.93) 
      for hip arthritis; KOOS-PS, 0.66 (0.52, 0.77); HOOS-PS, 0.82 (0.66, 0.91); 
      KOOS-QOL, 0.79 (0.69, 0.86); and HOOS-QOL, 0.67 (0.42, 0.83). MCID and moderate 
      improvement estimates in patients with knee arthritis were ICOAP pain scale, 18.5 
      and 26.7; KOOS-PS, 2.2 and 15.0; and KOOS-QOL, 8.0 and 15.6. A smaller sample in 
      patients with hip arthritis precluded MCID and moderate improvement estimates. 
      CONCLUSION: We found that ICOAP pain and KOOS-PS/HOOS-PS scales were reasonably 
      reliable in patients with hip OA. Reliability of these scales was much lower in 
      patients with knee arthritis. Thresholds for clinically meaningful change in pain 
      or function on these scales were estimated for patients with knee arthritis.
FAU - Singh, Jasvinder A
AU  - Singh JA
AD  - From the Medicine Service, Birmingham VA Medical Center and Department of 
      Medicine, University of Alabama; Center for Surgical Medical Acute Care Research 
      and Transitions, Birmingham VA Medical Center; Division of Epidemiology, School 
      of Public Health, University of Alabama, Birmingham, Alabama; Departments of 
      Health Sciences Research and Orthopedic Surgery, Mayo Clinic School of Medicine, 
      Rochester, Minnesota; Section of Rheumatology and Clinical Immunology, University 
      of Texas, M.D. Anderson Cancer Center; St. Luke's Episcopal Health System, 
      Houston, Texas, USA.
FAU - Luo, Ruili
AU  - Luo R
FAU - Landon, Glenn C
AU  - Landon GC
FAU - Suarez-Almazor, Maria
AU  - Suarez-Almazor M
LA  - eng
GR  - K24 AR053593/AR/NIAMS NIH HHS/United States
GR  - KL2 RR024151/RR/NCRR NIH HHS/United States
GR  - K24AR053593/AR/NIAMS NIH HHS/United States
GR  - 1 KL2 RR024151-01/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140115
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
SB  - IM
MH  - Aged
MH  - *Disability Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Hip/*physiopathology
MH  - Osteoarthritis, Knee/*physiopathology
MH  - Pain/*diagnosis/physiopathology
MH  - *Pain Measurement
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
PMC - PMC3943561
MID - NIHMS530555
OTO - NOTNLM
OT  - ARTHRITIS
OT  - HIP
OT  - KNEE
OT  - PAIN
OT  - RELIABILITY
OT  - SENSITIVITY TO CHANGE
COIS- Financial Conflict: There are no financial conflicts related to this work. J.A.S. 
      has received research and travel grants from Takeda and Savient; and consultant 
      fees from Savient, Regeneron, Takeda and Allergan. RL, GL, and MSA have no 
      financial interests related to this work.
EDAT- 2014/01/17 06:00
MHDA- 2014/10/29 06:00
PMCR- 2015/03/01
CRDT- 2014/01/17 06:00
PHST- 2014/01/17 06:00 [entrez]
PHST- 2014/01/17 06:00 [pubmed]
PHST- 2014/10/29 06:00 [medline]
PHST- 2015/03/01 00:00 [pmc-release]
AID - jrheum.130609 [pii]
AID - 10.3899/jrheum.130609 [doi]
PST - ppublish
SO  - J Rheumatol. 2014 Mar;41(3):509-15. doi: 10.3899/jrheum.130609. Epub 2014 Jan 15.